Celgene

Which of These 5 Will Be the Best-Selling Drug Worldwide in 2020?
Which of These 5 Will Be the Best-Selling Drug Worldwide in 2020?
Motley Fool
AbbVie
Humira
Celgene
Revlimid
Bristol-Myers Squibb
Opdivo
Merck
Keytruda
Biogen
aducanumab
Flag link:
Celgene Broadens Forma Deal, Adding $195M More for Drug R&D
Celgene Broadens Forma Deal, Adding $195M More for Drug R&D
Xconomy
Celgene
Forma Therapeutics
R&D
Flag link:
Big names, big companies back a cell therapy startup run by a high-profile regenerative med expert
Big names, big companies back a cell therapy startup run by a high-profile regenerative med expert
Endpoints
cell therapy
startups
regenerative medicine
Celgene
Hariri
R&D
Flag link:
An analysis of 2017 first half for pharmaceutical industry
An analysis of 2017 first half for pharmaceutical industry
GoInPharma
pharma industry
Pfizer
Sanofi
GSK
Roche
Celgene
Bristol-Myers Squibb
Flag link:
Celgene-partnered Antengene preps new China deals as $21M round lands
Celgene-partnered Antengene preps new China deals as $21M round lands
Endpoints
Celgene
Antengene
China
Flag link:
Ozanimod Could Drive Celgene’s Long-Term Growth
Ozanimod Could Drive Celgene’s Long-Term Growth
Market Realist
ozanimod
Celgene
Flag link:
The 2017 report card so far: Big Biotech largely trading up as pharma posts mixed results
The 2017 report card so far: Big Biotech largely trading up as pharma posts mixed results
Fierce Pharma
pharma stocks
Merck
Pfizer
AbbVie
Eli Lilly
Bristol-Myers Squibb
GSK
Roche
Sanofi
Bayer
Novo Nordisk
Celgene
Biogen
AstraZeneca
Flag link:
Eyeing an IPO, Sutro retools its $1B I/O deal with Celgene but stays focused on BCMA
Eyeing an IPO, Sutro retools its $1B I/O deal with Celgene but stays focused on BCMA
Endpoints
IPOs
Sutro
Celgene
BCMA
Flag link:
Idhifa approval furthers Celgene's diversification goals
Idhifa approval furthers Celgene's diversification goals
BioPharma Dive
Celgene
Idhifa
acute myeloid leukemia
Flag link:
Celgene Corporation Continues to Get It Done
Celgene Corporation Continues to Get It Done
Motley Fool
Celgene
earnings
Flag link:
Celgene shares surge 1.6% on second-quarter profit, revenue beats
Celgene shares surge 1.6% on second-quarter profit, revenue beats
Marketwatch
Celgene
earnings
Flag link:
Celgene to fork over $280M to wrap a whistleblower's Revlimid marketing claims
Celgene to fork over $280M to wrap a whistleblower's Revlimid marketing claims
Fierce Pharma
Celgene
Revlimid
whistleblowers
off-label
False Claims Act
Flag link:
These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet
These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet
Motley Fool
Biogen
aducanumab
JNJ
apalutamide
Eli Lilly
abemaciclib
AbbVie
Rova-T
Celgene
ozanimod
Flag link:
Biotechs Find Strength In Numbers In Treating Multiple Sclerosis
Biotechs Find Strength In Numbers In Treating Multiple Sclerosis
Investors Business Daily
MS
multiple sclerosis
Roche
Celgene
Novartis
Biogen
ozanimod
Gilenya
Ocrevus
Extavia
Flag link:
Amgen's battered Kyprolis nabs a survival win, slashing death risk in Revlimid-chemo combo
Amgen's battered Kyprolis nabs a survival win, slashing death risk in Revlimid-chemo combo
Fierce Pharma
Amgen
Kyprolis
Revlimid
Celgene
Takeda
Velcade
Multiple Myeloma
Flag link:
5 Pharma & Biotech Stocks That Could Be Big Winners in Q2 Earnings
5 Pharma & Biotech Stocks That Could Be Big Winners in Q2 Earnings
Yahoo/Zacks.com
earnings
Merck
Eli Lilly
Celgene
Gilead Sciences
Shire
Flag link:
These 5 Cancer Drugs Will Be the Biggest Winners 5 Years From Now
These 5 Cancer Drugs Will Be the Biggest Winners 5 Years From Now
Motley Fool
Celgene
Revlimid
Bristol-Myers Squibb
Opdivo
Merck
Keytruda
AbbVie
JNJ
Imbruvica
Pfizer
Ibrance
cancer
Flag link:
What Gilead Could Learn From Celgene
What Gilead Could Learn From Celgene
Seeking Alpha
Gilead Sciences
Celgene
Flag link:
What the FDA's Hold on Three Merck Studies Means for Other Drug Makers
What the FDA's Hold on Three Merck Studies Means for Other Drug Makers
TheStreet.com
Merck
Keytruda
FDA
clinical trials
Multiple Myeloma
Bristol-Myers Squibb
AstraZeneca
Celgene
Flag link:
Billions of Dollars on the Line for Celgene With These 3 Small Biotechs
Billions of Dollars on the Line for Celgene With These 3 Small Biotechs
Motley Fool
Celgene
Juno Therapeutics
Acceleron
Bluebird Bio
Flag link: